Key result
RAAS inhibitors are not linked to increased severe illness or mortality in hypertensive COVID-19 patients.
Why the study?
High-quality evidence for whether the use of RAAS inhibitors worsens clinical outcomes for patients with COVID-19 was lacking.
Does treatment with RAAS inhibitors worsen severe illness or mortality in patients with hypertension and COVID-19?
Meta-Analysis
Does treatment with RAAS inhibitors worsen severe illness or mortality in patients with hypertension and COVID-19?
Effect estimate: OR 1.00 (95% CI 0.88-1.14)
The use or continuation of RAAS inhibitors in patients with hypertension and COVID-19 does not worsen disease severity or increase mortality, supporting current guidelines to continue these medications.
No takes yet. Share an insight, caveat, or question.
RAAS inhibitors may be continued safely in hypertensive COVID-19 patients; reinforces guidelines and prior safety data.
Zhang et al. (2022) conducted a meta-analysis in hypertension and COVID-19. renin-angiotensin-aldosterone system (RAAS) inhibitors vs. not treated with RAAS inhibitors was evaluated on severe illness (OR 1.00, 95% CI 0.88-1.14). The use of RAAS inhibitors was not associated with an increased risk of severe illness (OR 1.00; 95% CI 0.88-1.14) or mortality (OR 0.96; 95% CI 0.83-1.11) in patients with hypertension and COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: